Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status
Authors' conclusion
In UK primary care, GLP-1RA persistence was suboptimal and dose escalation was frequently delayed across all patient stratifications, including individuals with established CVD.
Study context
- Population
- Adults with T2D initiating GLP-1RAs between 1 March 2018 and 30 June 2023, with follow-up ≥1-year, UK primary careGLP-1RA initiators
- Participants
- 8,200 adults
- Exposure
- GLP-1RA persistence and dose titration by agent, obesity status, cardiovascular disease (CVD) history and sex
- Outcome
- Absolute risk of discontinuation
- Follow-up
- 1 year
Methodological detailsUK primary care, IQVIA Medical Research Data (IMRD)
- UK primary care
- IQVIA Medical Research Data (IMRD)
Main finding
As reported in the abstract
Discontinuation risk
- Overall 1-year discontinuation risk
- 41.1% (95% CI 40.1-42.2)
Observational data: associations, not effects.
Further findings
Subcutaneous semaglutide 1 mg at prescription 5, by BMI
Semaglutide dose titration after 4 weeks (subcutaneous/oral)
- Reached recommended maintenance doses
- 58%
- Remained on starting doses
- 21%
Most common doses at prescription 10
- Subcutaneous semaglutide 0.5/1 mg
- 44.0%/48.6%
- Oral semaglutide 7/14 mg
- 50.2%/36.6%
- Dulaglutide 0.75/1.5/3 mg
- 20.4%/71.5%/6.7%
Subcutaneous semaglutide 1 mg at prescription 5, by BMI
- Faster dose escalation with higher BMI and subcutaneous semaglutide
Additional analyses (e.g., by CVD history)
- No further heterogeneity
Original publication
Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status. Diabetes Obes Metab. Published 17 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →